Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Biopharma save search
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
ABBV | News | $169.965 1.24% 890K
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
abbvie cell biopharma collaboration car-t
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL AmyloidosisVirtual Event to be held on November 29, 2023 at 4:15 p.m. ET
Published: 2023-11-22 (Crawled : 17:00) - biospace.com/
IMMX | $2.135 0.24% 3.7K
|
|
| O: 1.91%
H: 3.85%
C: 3.04%
nxc-201 candidate cell biopharma car-t therapy
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
Published: 2023-11-22 (Crawled : 14:00) - globenewswire.com
IMMX | $2.135 0.24% 3.7K
|
|
| O: 1.91%
H: 3.85%
C: 3.04%
nxc-201 candidate cell biopharma car-t therapy
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
Published: 2023-03-31 (Crawled : 12:20) - globenewswire.com
IMMX | $2.135 0.24% 3.7K
|
|
| O: 2.33%
H: 6.24%
C: 3.41%
JNJ | News | $148.24 -0.59% 1.6M
|
Health Technology
|
| O: 0.23%
H: 0.91%
C: 0.79%
nxc-201 drug approved food biopharma
Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
Published: 2023-02-09 (Crawled : 19:00) - globenewswire.com
IMMX | $2.135 0.24% 3.7K
|
|
| O: -5.14%
H: 4.53%
C: -12.08%
nxc-201 biopharma expansion meeting t-cell trial response
Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic
Published: 2022-11-10 (Crawled : 23:00) - prnewswire.com
RGBP | $0.7 1.5K
|
Manufacturing
|
| O: -1.89%
H: 7.69%
C: 1.92%
biopharma car-t
Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors
Published: 2022-08-25 (Crawled : 22:00) - biospace.com/
RGBP | $0.7 1.5K
|
Manufacturing
|
| O: 0.0%
H: 10.53%
C: 3.16%
biopharma immunotherapy car-t
Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate
Published: 2022-06-21 (Crawled : 13:00) - biospace.com/
KRBP | $2.6 2.7K
|
Health Technology
|
| O: 23.76%
H: 0.0%
C: 0.0%
biopharma candidate t-cell
Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement
Published: 2022-06-07 (Crawled : 12:00) - biospace.com/
KRBP | $2.6 2.7K
|
Health Technology
|
| O: 100.0%
H: 7.17%
C: -16.33%
biopharma research
Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Published: 2022-05-11 (Crawled : 12:20) - prnewswire.com
LLY | News | $739.11 1.06% 320K
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
biopharma disease
Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2021-12-09 (Crawled : 19:00) - biospace.com/
QGEN | $41.58 0.87% 150K
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
QGEN | $41.58 0.87% 150K
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
diagnostic treatment biopharma test t-cell
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2021-12-09 (Crawled : 08:00) - biospace.com/
QGEN | $41.58 0.87% 150K
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
QGEN | $41.58 0.87% 150K
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
diagnostic treatment biopharma test t-cell
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
ADCT | $4.99 6.62% 82K
|
Health Technology
|
| O: 0.82%
H: 0.25%
C: -4.96%
phase 2 biopharma china trial t-cell
Gainers vs Losers
| 89% | 11% |
Top 10 Gainers
MTTR | News M | $4.65 167.24% 9.8M
|
AGBA | $2.355 88.4% 34M
|
Finance
EDBL | News | $6.94 84.57% 1.4M
|
CZOO | $8.77 75.75% 11M
|
VNRX | $0.84 40.0% 2.6M
|
Health Technology
OPRT | News | $3.01 33.78% 6.8M
|
Finance
MLEC | $1.81 29.29% 2M
|
n/a
CMAX | $4.12 28.35% 65K
|
Manufacturing
MTC | $2.0 28.21% 1.7M
|
Technology Services
PEGY | $0.0586 27.95% 130M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.